Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analyst consensus: Fourteen analysts give Cogent an average rating of "Moderate Buy" (1 sell, 2 hold, 9 buy, 2 strong buy) with a 1‑year average price target of $43.45 and several firms raising targets into the $52–$55 range while a few maintain sell calls.
• Market and earnings snapshot: COGT opened at $36.63 with a $6.26 billion market cap, a 1‑year range of $4.55–$43.73, and reported a quarterly EPS loss of ($0.55) versus a ($0.51) estimate, while analysts forecast about -$2.14 EPS for the year.
• Company focus: Cogent is a clinical‑stage biopharma developing an orally available, selective CSF1R inhibitor aimed at reprogramming the tumor microenvironment and is in early‑stage trials for solid tumors.

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have received an average rating of "Moderate Buy" from the fourteen analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $43.4545.

Several equities analysts have weighed in on COGT shares. Piper Sandler lifted their price objective on shares of Cogent Biosciences from $39.00 to $52.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cogent Biosciences in a research report on Friday, April 10th. Wedbush reiterated an "outperform" rating and set a $55.00 price objective on shares of Cogent Biosciences in a research report on Tuesday, March 17th. HC Wainwright lifted their price objective on shares of Cogent Biosciences to $52.00 and gave the stock a "buy" rating in a research report on Tuesday, January 6th. Finally, Wall Street Zen cut shares of Cogent Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, January 31st.

Hedge Funds Weigh In On Cogent Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. CWM LLC grew its position in Cogent Biosciences by 4.9% during the 4th quarter. CWM LLC now owns 5,858 shares of the technology company's stock worth $208,000 after purchasing an additional 276 shares in the last quarter. Steward Partners Investment Advisory LLC grew its position in Cogent Biosciences by 16.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,159 shares of the technology company's stock worth $77,000 after purchasing an additional 300 shares in the last quarter. Optimize Financial Inc grew its position in Cogent Biosciences by 1.4% during the 4th quarter. Optimize Financial Inc now owns 33,024 shares of the technology company's stock worth $1,173,000 after purchasing an additional 472 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Cogent Biosciences by 35.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the technology company's stock worth $66,000 after purchasing an additional 488 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Cogent Biosciences by 2.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,014 shares of the technology company's stock valued at $888,000 after acquiring an additional 527 shares in the last quarter.

Cogent Biosciences Price Performance

NASDAQ COGT opened at $36.63 on Monday. The stock has a market capitalization of $6.26 billion, a P/E ratio of -16.96 and a beta of 0.37. Cogent Biosciences has a 1 year low of $4.55 and a 1 year high of $43.73. The business's fifty day moving average is $36.47 and its two-hundred day moving average is $34.40. The company has a debt-to-equity ratio of 0.41, a quick ratio of 14.23 and a current ratio of 14.23.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The technology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, research analysts forecast that Cogent Biosciences will post -2.14 earnings per share for the current fiscal year.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.